Microbicide Research and Development to Advance HIV Prevention Technologies through Responsive Innovation and Excellence: MATRIX
The mission of MATRIX, a program funded by USAID, is to develop an innovative range of acceptable, affordable, scalable, and ultimately deliverable products designed to address the unmet needs of women at risk of HIV.
CONRAD has joined eighteen partner organizations in the United States and Sub-Saharan Africa who are experts in product development, clinical trials, social and behavioral research, and market and business case development to develop multiple products:
- Cabotegravir Injectable Hydrogel Depot (+ levonorgestrel)
- Cabotegravir Pellet Implants (+ levonorgestrel)
- TAF/ EVG On-Demand Dual Compartment (Vaginal/Rectal) Fast Dissolving Insert
For more information about the MATRIX program and partners, visit the MATRIX Consortium.
This program was made possible by the generous support of the American people through the U.S. Agency for International Development (USAID) and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). The contents of this page are the responsibility of CONRAD and do not necessarily reflect the views of USAID, PEPFAR, or the United States Government.
